Inflammasome Therapeutics
MA - NewtonBiotechnology
Focus: Inflammasome Therapeutics is a pre-revenue biotechnology company focused on therapies for degenerative diseases in neurology and endocrinology, with a platform in sustained-release drug delivery. The company is in early-stage clinical development with a modest pipeline of 5 ongoing trials.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Inflammasome Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Inflammasome Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Kamuvudine-9
Thyroid Eye DiseaseClinical Trials (1)
NCT06467435Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
Phase 1Help build intelligence for Inflammasome Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.